ZIOPHARM (ZIOP) Bullish Stance Reiterated at BMO Capital Following MSKCC Pre-Clinical CAR-T Data
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $15 price target on ZIOPHARM Oncology (NASDAQ: ZIOP) after scientists ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
